Physician
Retina Consultants of Southern Cal Medical Associates INC
Retina Consultants of Southern Cal Medical Associates INC was paid $2.55M by Medicaid between Jan 2018 and Nov 2024, across 17 billing codes. Its largest line is 67028, Intravitreal injection of a pharmacologic agent — 24% of everything it billed.
33Billing provider infoRETINA CONSULTANTS OF SOUTHERN CAL MEDICAL ASSOCIATES INC
RIVERSIDE, CA 92503
RIVERSIDE, CA 92503
33aNPI1710046842assigned 12/06/2006
33bProvider typeOphthalmology Physician
28Total paid$2.55M
24GClaims38,241
24DCodes billed17
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Ophthalmology Physician providers in California
Rank by total paid#41 of 759
Median peer was paid$35K
This provider vs. median72×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,136 | $217K | |
| 2019 | 4,626 | $232K | |
| 2020 | 4,237 | $209K | |
| 2021 | 4,255 | $302K | |
| 2022 | 4,983 | $429K | |
| 2023 | 7,835 | $612K | |
| 2024incomplete | 8,169 | $552K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 67028 | Intravitreal injection of a pharmacologic agent | 24% | 8,386 | 8,042 | $618K |
| J9035 | Injection, bevacizumab, 10 mg | 15% | 5,328 | 5,082 | $371K |
| J0178 | Injection, aflibercept, 1 mg | 13% | 310 | 307 | $344K |
| 92134 | 12% | 12,553 | 12,201 | $302K | |
| J2778 | Injection, ranibizumab, 0.1 mg | 7.9% | 301 | 296 | $202K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.7% | 2,554 | 2,541 | $172K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 5.8% | 296 | 292 | $148K |
| 92250 | 4.0% | 3,967 | 3,913 | $103K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 3.6% | 1,304 | 1,290 | $93K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.4% | 827 | 823 | $86K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.2% | 544 | 525 | $31K |
| 92235 | 1.0% | 316 | 316 | $26K |
5 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARLSON, JOHN (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Los Palos Gastroenterology INC | Salinas, CA | $394K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.